RecruitingPHASE2, PHASE3NCT06647498
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Studying NON RARE IN EUROPE: Alzheimer disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Washington University School of Medicine
- Principal Investigator
- Eric M McDade, DOWashington University School of Medicine
- Intervention
- Remternetug(drug)
- Enrollment
- 280 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2034
Study locations (30)
- University of Alabama in Birmingham, Birmingham, Alabama, United States
- University of California San Diego Medical Center, La Jolla, California, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Emory University, Atlanta, Georgia, United States
- Advocate Lutheran General Hospital, Park Ridge, Illinois, United States
- Indiana University School of Medicine, Indianapolis, Indiana, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- New York University Medical Center, New York, New York, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Butler Hospital, Providence, Rhode Island, United States
- Kerwin Research and Memory Center, Dallas, Texas, United States
- University of Washington, Seattle, Washington, United States
- Instituto de Investigaciones Neurologicas Raul Carrea, FLENI, Ciudad Autonoma de Buenos Aire, Argentina
- Neuroscience Research Australia, Randwick, New South Wales, Australia
- Alzheimer's Research Australia, Melbourne, Victoria, Australia
- +15 more locations on ClinicalTrials.gov
Collaborators
Alzheimer's Association · Eli Lilly and Company · National Institute on Aging (NIA) · GHR Foundation · Private Donors
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06647498 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Alzheimer disease
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT07250113WeCareToFeedDysphagia to Reduce Care-partner Burden Full-scale RCTNorthwell Health
- RECRUITINGNCT07457138Lombard Cohort of Brain Health ServicesUniversity of Milano Bicocca
- RECRUITINGNANCT07286448Personalized Digital Training for COGnitive FITness in Mild Cognitive ImpairmentGiovanna Zamboni
- ACTIVE NOT RECRUITINGNANCT07479914Art of Memory for Cognitive Enhancement in the Monza Brain Health ServiceUniversity of Milano Bicocca
- RECRUITINGNANCT07212504Effect of Accelerated Neuromodulation of Anterior Cingulate Cortex to Enhance Cognition in Older Adults With Mild Memory ProblemsRotman Research Institute at Baycrest
- ENROLLING BY INVITATIONNANCT07168824An Open Label Trial Evaluating the Efficacy of Lacticaseibacillus Paracasei PS23 on CognitionChi-Chang Huang
- RECRUITINGNCT07402161The Signature of Alzheimer's Disease in Subjective Cognitive DeclineIRCCS Policlinico S. Donato
- ACTIVE NOT RECRUITINGNANCT07350226Electro-acupuncture for SCD With DepressionThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School